Oral therapies for pulmonary arterial hypertension: Endothelin receptor antagonists and phosphodiesterase-5 inhibitors

Clinics in Chest Medicine

Volumn 34, Issue 4, 2013, Pages 811-824

  Channick, Richard ^a   Preston, Iona ^b   Klinger, James R ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b TUFTS UNIVERSITY   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Endothelin receptor antagonists; Oral therapy; Phosphodiesterase 5 inhibitors; Pulmonary arterial hypertension

Indexed keywords

AMBRISENTAN; BOSENTAN; CYCLOSPORIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; SILDENAFIL; TADALAFIL; VARDENAFIL;

ABNORMAL LABORATORY RESULT; ANEMIA; BINDING AFFINITY; BINDING SITE; CONGENITAL HEART DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; ENDOTHELIN 1 GENE; EPISTAXIS; FLUSHING; GENE; HEADACHE; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYPERTRANSAMINASEMIA; LUNG EMBOLISM; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MYALGIA; NONHUMAN; NOSE OBSTRUCTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SURVIVAL RATE; TREATMENT DURATION;

ENDOTHELIN RECEPTOR ANTAGONISTS; ORAL THERAPY; PHOSPHODIESTERASE-5 INHIBITORS; PULMONARY ARTERIAL HYPERTENSION;

ADMINISTRATION, ORAL; CARBOLINES; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; RECEPTORS, ENDOTHELIN; SULFONES;

EID: 84888183998     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2013.09.005     Document Type: Review

References (85)

1. Yanagisawa M., Kurihara H., Kimura S., et al. Anovel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
2. Inoue A., Yanagisawa M., Kimura S., et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 1989, 86:2863-2867.
3. Mattoli S., Mezzetti M., Riva G., et al. Specific binding of endothelin on human bronchial smooth muscle cells in culture and secretion of endothelin-like material from bronchial epithelial cells. Am J Respir Cell Mol Biol 1990, 3:145-151.
4. Yu J., Davenport A. Secretion of endothelin-1 and endothelin-3 by human cultured vascular smooth muscle cells. Br J Pharmacol 1995, 114:551-557.
5. Ehrenreich H., Anderson R.W., Fox C.H., et al. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. JExp Med 1990, 172:1741-1748.
6. Miyauchi T., Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 1999, 61:391-415.
7. Michael J., Markewitz B. Endothelins and the lung. Am J Respir Crit Care Med 1996, 154:555-581.
8. Yoshimoto S., Ishizaki Y., Sasaki T., et al. Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells. Stroke 1991, 22:378-383.
9. Takuwa Y., Kasuya Y., Takuwa N., et al. Endothelin receptor is coupled to phospholipase C via pertussis toxin insensitive guanine nucleotide binding regulatory protein in vascular smooth muscle cells. JClin Invest 1990, 85:653-658.
10. Chua B.H., Krebs C.J., Chua C.C., et al. Endothelin stimulates protein synthesis in smooth muscle cells. Am J Physiol 1992, 262:E412-E416.
11. Davie N., Haleen S.J., Upton P.D., et al. ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002, 165:398-405.
12. Hirata Y., Emori T., Eguchi S. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. JClin Invest 1993, 91:1367-1373.
13. Masaki T. Possible role of endothelin in endothelial regulation of vascular tone. Annu Rev Pharmacol Toxicol 1995, 35:235-255.
14. Dupuis J., Jasmin J.F., Prié S., et al. Importance of local production of endothelin-1 and of the ETB receptor in the regulation of pulmonary vascular tone. Pulm Pharmacol Ther 2000, 13:135-140.
15. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. NEngl J Med 1993, 328:1732-1739.
16. Bando K., Vijayaraghavan P., Turrentine M.W., et al. Dynamic changes of endothelin-1, nitric oxide, and cyclic GMP in patients with congenital heart disease. Circulation 1997, 96(Suppl 9):II-346-II-351.
17. Kim H., Yung G.L., Marsh J.J., et al. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J 2000, 15:640-648.
18. Bauer M., Wilkens H., Langer F., et al. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hyper- tension. Circulation 2002, 105:1034-1036.
19. Galié N., Badesch D., Oudiz R., et al. Ambrisentan therapy for pulmonary arterial hypertension. JAm Coll Cardiol 2005, 46:529-535.
20. Galiè N., Olschewski H., Oudiz R.J., et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008, 117(23):3010-3019.
21. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo controlled study. Lancet 2001, 358:1119-1123.
22. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. NEngl J Med 2002, 346(12):896-903.
23. Galiè N., Rubin L.J., Hoeper M., et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet 2008, 37:2093-2100.
24. Galiè N., Beghetti M., Gatzoulis M.A., et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006, 114(1):48-54.
25. McLaughlin V.V., Sitbon O., Badesch D.B., et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005, 25:244-249.
26. Klinger J.R. The nitric oxide/cGMP signaling pathway in pulmonary hypertension. Clin Chest Med 2007, 28(1):143-167.
27. Frostell C.G., Blomqvist H., Hedenstierna G., et al. Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilation. Anesthesiology 1993, 78(3):427-435.
28. Wanstall J.C., Hughes I.E., O'Donnell S.R. Evidence that nitric oxide from the endothelium attenuates inherent tone in isolated pulmonary arteries from rats with hypoxic pulmonary hypertension. Br J Pharmacol 1995, 114(1):109-114.
29. Hill N.S., Klinger J.R., Warburton R.R., et al. Brain natriuretic peptide: possible role in the modulation of hypoxic pulmonary hypertension. Am J Physiol 1994, 266(3 Pt 1):L308-L315.
30. Klinger J.R., Warburton R.R., Pietras L., et al. Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol 2002, 282(1):H58-H65.
31. Zhao L., Long L., Morrell N.W., et al. NPR-A-deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension. Circulation 1999, 99(5):605-607.
32. Charloux A., Chaouat A., Piquard F., et al. Renal hyporesponsiveness to brain natriuretic peptide: both generation and renal activity of cGMP are decreased in patients with pulmonary hypertension. Peptides 2006, 27(11):2993-2999.
33. Kharitonov S.A., Cailes J.B., Black C.M., et al. Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 1997, 52(12):1051-1055.
34. Klinger J.R., Abman S.H., Gladwin M.T. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013, [Epub ahead of print].
35. Lincoln T.M., Dey N., Sellak H. Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. JAppl Physiol 2001, 91:1421-1430.
36. Surks H.K., Mochizuki N., Kasai Y., et al. Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase I alpha. Science 1999, 286(5444):1583-1587.
37. Corbin J.D., Turko I.V., Beasley A., et al. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem 2000, 267:2760-2767.
38. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006, 109(3):366-398.
39. Keravis T., Lugnier C. Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs. Curr Pharm Des 2010, 16(9):1114-1125.
40. Kass D.A., Champion H.C., Beavo J.A. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 2007, 101(11):1084-1095.
41. Maclean M.R., Johnston E.D., Mcculloch K.M., et al. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. JPharmacol Exp Ther 1997, 283(2):619-624.
42. Hanson K.A., Ziegler J.W., Rybalkin S.D., et al. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am J Physiol 1998, 275:L931-L941.
43. Mikhail G.W., Prasad S.K., Li W., et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J 2004, 25:431-436.
44. Ghofrani H.A., Pepke-Zaba J., Barbera J.A., et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. JAm Coll Cardiol 2004, 43:68S-72S.
45. Michelakis E., Tymchak W., Lien D., et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002, 105(20):2398-2403.
46. Weimann J., Ullrich R., Hromi J., et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 2000, 92(6):1702-1712.
47. Zhao L., Mason N.A., Morrell N.W., et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001, 104(4):424-428.
48. Richalet J.P., Gratadour P., Robach P., et al. Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. Am J Respir Crit Care Med 2005, 171(3):275-281.
49. Angulo J., Gadau M., Fernandez A., et al. IC351 enhances nitric oxide-mediated relaxation of human arterial and trabecular penile smooth muscle. Diabetologia 2001, 44(S1):A295.
50. Preston I.R., Klinger J.R., Landzberg M.J., et al. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 2001, 120:866-872.
51. Schermuly R.T., Krupnik E., Tenor H., et al. Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. Am J Respir Crit Care Med 2001, 164:1694-1700.
52. Schermuly R.T., Roehl A., Weissmann N., et al. Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001, 281:L1361-L1368.
53. Ichinose F., Erana-Garcia J., Hromi J., et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 2001, 29:1000-1005.
54. Preston I.R., Hill N.S., Gambardella L.S., et al. Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension. Exp Biol Med (Maywood) 2004, 229:920-925.
55. Sebkhi A., Strange J., Phillips S., et al. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 2003, 107:3230-3235.
56. Schermuly R., Kreisselmeier K., Ghofrani H., et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004, 169:39-45.
57. Zhao L., Mason N., Strange J., et al. Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic peptide activity. Circulation 2003, 107:234-237.
58. Leuchte H.H., Schwaiblmair M., Baumgartner R.A., et al. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest 2004, 125:580-586.
59. Preston I.R., Klinger J.R., Houtches J., et al. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. Respir Med 2005, 99:1501-1510.
60. Wilkens H., Guth A., Konig J., et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001, 104:1218-1222.
61. Bharani A., Mathew V., Sahu A., et al. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J 2003, 55:55-59.
62. Sastry B.K., Narasimhan C., Reddy N.K., et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. JAm Coll Cardiol 2004, 43:1149-1153.
63. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. NEngl J Med 2005, 353:2148-2157.
64. Ricart A., Maristany J., Fort N., et al. Effects of sildenafil on the human response to acute hypoxia and exercise. High Alt Med Biol 2005, 6:43-49.
65. Aldashev A.A., Kojonazarov B.K., Amatov T.A., et al. Phosphodiesterase type 5 and high altitude pulmonary hypertension. Thorax 2005, 60:683-687.
66. Ghofrani H., Schermuly R., Rose F., et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003, 167:1139-1141.
67. Ghofrani H.A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002, 360:895-900.
68. Lepore J.J., Maroo A., Bigatello L.M., et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 2005, 127:1647-1653.
69. Skoumal R., Chen J., Kula K., et al. Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur Urol 2004, 46(3):362-369.
70. Tolrà J.R., Campaña J.M., Ciutat L.F., et al. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. JSex Med 2006, 3(5):901-909.
71. Ghofrani H.A., Voswinckel R., Reichenberger F., et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. JAm Coll Cardiol 2004, 44(7):1488-1496.
72. Palmieri E.A., Affuso F., Fazio S., et al. Tadalafil in primary pulmonary arterial hypertension. Ann Intern Med 2004, 141(9):743-744.
73. Mukhopadhyay S., Sharma M., Ramakrishnan S., et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation 2006, 114(17):1807-1810.
74. Aggarwal P., Patial R.K., Negi P.C., et al. Oral tadalafil in pulmonary artery hypertension: a prospective study. Indian Heart J 2007, 59(4):329-335.
75. Bharani A., Patel A., Saraf J., et al. Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart J 2007, 59(4):323-328.
76. Galie N., Brundage B.H., Ghofrani H.A., et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 11:2894-2903.
77. Arneson C., McDevitt S., Klinger J.R. Tadalafil in geriatric patients with pulmonary arterial hypertension. Chest 2010, 138:367A.
78. Chen H.C., Wang C.S., Chuang S.H., et al. Pulmonary embolism after tadalafil ingestion. Pharm World Sci 2008, 30(5):610-612.
79. Tripathi A., O'Donnell N.P. Branch retinal artery occlusion; another complication of sildenafil. Br J Ophthalmol 2000, 84(8):934-935.
80. Akash R., Hrishikesh D., Amith P., et al. Case report: association of combined nonarteritic anterior ischemic optic neuropathy (NAION) and obstruction of cilioretinal artery with overdose of Viagra. JOcul Pharmacol Ther 2005, 21(4):315-317.
81. Peter N.M., Singh M.V., Fox P.D. Tadalafil-associated anterior ischaemic optic neuropathy. Eye (Lond) 2005, 19(6):715-717.
82. Bollinger K., Lee M.S. Recurrent visual field defect and ischemic optic neuropathy associated with tadalafil rechallenge. Arch Ophthalmol 2005, 123(3):400-401.
83. Wilkins M.R., Paul G.A., Strange J.W., et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 2005, 171(11):1292-1297.
84. Udeoji D.U., Schwarz E.R. Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension. Ther Adv Respir Dis 2013, 7(1):39-49.
85. Oudiz R.J., Brundage B.H., Galiè N., PHIRST Study Group, et al. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. JAm Coll Cardiol 2012, 60(8):768-774.